

THE FOLLOWING ANNOUNCEMENT IS BEING MADE PURSUANT TO THE REQUIREMENTS OF RULE 19.6(C) OF THE CITY CODE ON TAKEOVERS AND MERGERS, WHICH, AMONGST OTHER THINGS, REQUIRES A PARTY TO AN OFFER TO MAKE AN ANNOUNCEMENT AT THE END OF THE PERIOD OF 12 MONTHS FROM THE DATE ON WHICH THE OFFER PERIOD ENDED CONFIRMING WHETHER IT HAS TAKEN, OR NOT TAKEN, THE COURSE OF ACTION SET OUT IN ITS STATED INTENTIONS

31 May 2023

Brand Architekts Group PLC

("Brand Architekts" or the "Group")

Rule 19.6(c) confirmation with respect to stated post-offer intentions in regard to InnovaDerma Plc

Brand Architekts Group Plc announces that, further to the completion of the recommended merger with InnovaDerma Plc, which became effective by means of a Court-sanctioned Scheme of Arrangement on 31 May 2022, it has duly confirmed in writing to The Panel on Takeovers and Mergers in accordance with the requirements of Rule 19.6(c) of the City Code on Takeovers and Mergers ("the Code") that it has complied with the post-offer statements of intent made pursuant to Rules 2.7(c)(viii) and 24.2 of the Code, as originally detailed in the announcement of 31 March 2022 and the scheme document published on 25 April 2022.

For further information please contact:

Brand Architekts Group PLC
Quentin Higham / Tom Carter

via Alma

Singer Capital Markets
Shaun Dobson / Jen Boorer

(Nominated adviser and broker)

020 7496 3000

Alma PR
Josh Royston / Sam Modlin

0203 405 0205

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

OUPFZGFKKGLGFZM